Genentech’s Subcutaneous Tecentriq Shows Non-Inferiority To I.V. Formulation
Executive Summary
The Roche affiliate hopes to bring subcutaneous Tecentriq to market, offering patient and clinician advantages while also beating Merck’s Keytruda and Bristol’s Opdivo to the finish line
You may also be interested in...
BMS Moves Closer To Subcutaneous Opdivo With Phase III Trial Success
A Phase III trial testing subcutaneous nivolumab versus the intravenous product hits pharmacokinetic and efficacy endpoints. BMS, Roche and Merck & Co. all are seeking subcutaneous versions of their anti-PD-1/L1 blockbusters.
Roche Forced To Wait By FDA For SC Tecentriq Okay
The Swiss major’s partner Halozyme has revealed that the US launch for the subcutaneous version of the checkpoint inhibitor Tecentriq will be put back until 2024 following questions from the Food and Drug Administration about manufacturing processes.
Roche Eyes Adjuvant HCC Setting After Phase III Tecentriq Combination Success
The firm’s Tecentriq has bounced back from recent setbacks with a pivotal success in the adjuvant liver cancer setting.